Trials / Terminated
TerminatedNCT02744287
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.
Detailed description
Former Sponsor Bellicum Pharmaceuticals Study ended prior to the start of Phase 2
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BPX-601 | Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain |
| DRUG | Rimiducid | Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence |
Timeline
- Start date
- 2016-11-30
- Primary completion
- 2023-03-14
- Completion
- 2023-03-14
- First posted
- 2016-04-20
- Last updated
- 2026-02-23
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02744287. Inclusion in this directory is not an endorsement.